A

Market Sentiment for A

Sentiment and Price Analysis

-0.97-0.480.000.480.97Sentiment Score99.29128.25157.20Stock PriceNovFebMayAugNovFeb

Live Market Insights

Live Market Sentiment
Positive (0.1006)
(Latest daily score)
Predicted Return
7.36%
7-day sentiment average
Advisory Opinion
Hold
Derived from sentiment trend
News Items (period)
1,022

Recent Headlines for A

The table below gives each of the most recent headlines of the stock and the negative, neutral, positive aggregated sentiment score.

DateHeadlineSourceSentiment
2026-04-03How Investors May Respond To Agilent Technologies (A) CRISPR Patent Setback And New BioTek Cytation 9 LaunchSimply Wall St.Neutral (0.0876)
2026-04-033 Profitable Stocks We’re Skeptical OfStockStoryPositive (0.1006)
2026-04-02[Latest] Global Environmental Mass Spectrometry Market Size/Share Worth USD 6.47 Billion by 2035 at a 7.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)GlobeNewswirePositive (0.1483)
2026-04-01Synthego Welcomes Supreme Court Order Finalizing Invalidation of Agilent CRISPR PatentsPR NewswireStrong Positive (0.4253)
2026-04-01Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode ReaderBusiness WirePositive (0.1294)
2026-03-29The Often-Missed Corner of Healthcare That Wall Street Is LovingMarketBeatNeutral (-0.0107)
2026-03-27Why Is Agilent (A) Down 6.2% Since Last Earnings Report?ZacksStrong Negative (-0.9583)
2026-03-27Is It Time To Consider Buying Agilent Technologies, Inc. (NYSE:A)?Simply Wall St.Neutral (0.0344)
2026-03-27Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDxTipRanksStrong Positive (0.8637)
2026-03-26Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) CarcinomaBusiness WireStrong Positive (0.9167)